Cargando…
Advances in cancer research. Volume 97 /
Held at the Karolinska Instituet, in Stockholm, Sweden, a recent Nobel Minisymposium, "Molecular Oncology - From Bench to Bedside," marked a very special event-the celebration of George and Eva Klein's combined 160th birthdays. To honor this occasion, Volume 97 of Advances in Cancer R...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Academic Press,
2007.
|
| Colección: | Advances in cancer research ;
97 |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Cancer Research; Copyright Page; Contents; Contributors to Volume 97; Dedication; George Vande Woude; Klas Wiman; Olle Ringdeacuten; Carl-Henrik Heldin and Arne Oumlstman; Alan R. Fersht; Peter H. Krammer; Kenneth Nilsson; Marie Henriksson; Chapter 1: Structural Biology of the Tumor Suppressor p53 and Cancer-Associated Mutants; Abbreviations; I. Introduction; II. The Domain Structure of Human p53; III. The Structure of the DNA-Binding Domain; A. p53C Has Evolved to Be Unstable; B. Design of a Superstable Variant of p53C; C. From Core Domain to the Full-Length Protein
- IV. Effects of Common Cancer MutationsA. Structural Effects of Oncogenic Mutations; V. Rescuing Mutant p53; A. Lessons from Second-Site Suppressor Mutations; B. p53C as a Drug Target; VI. Concluding Remarks; References; Chapter 2: Immunotherapy by Allogeneic Stem Cell Transplantation; I. Introduction; II. Graft-Versus-Host Disease; A. Mechanisms; B. Acute GVHD; C. Chronic GVHD; D. Prevention and Treatment of GVHD; III. The Graft-Versus-Leukemia Effect; A. Preliminary Studies; B. Tumor Burden; C. Enhancement of Graft-Versus-Leukemia; D. Cytotoxic T Cells
- E. Pathophysiology of Graft-Versus-LeukemiaIV. NK Cells; V. Early Detection of Relapse; A. Minimal Residual Disease; B. Mixed Chimerism; C. Molecular Detection of CML; D. Immunoglobulin and T Cell Receptor Gene Rearrangement; VI. The Graft-Versus-Cancer Effect; A. Immunotherapy Against Cancer; B. Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation; C. Reduced Intensity Conditioning and Stem Cell Transplantation for Renal Carcinoma; D. Reduced Intensity Conditioning and Stem Cell Transplantation for Various Solid Tumors
- E. Combined Liver Transplantation and Stem Cell Transplantation for Liver CancerF. Future of Stem Cell Transplantation for Solid Cancers; VII. Mesenchymal Stem Cells; A. Surface Markers and Homing; B. Immunity and Safety of MSCs; C. Immunomodulation by MSC; D. Immunosuppressive Mechanisms by MSCs; VIII. Future Directions; Acknowledgments; References; Chapter 3: Mnt Takes Control as Key Regulator of the Myc/Max/Mxd Network; I. Myc: The Most Frequently Deregulated Oncogene in Human Tumors; A. Myc in Control of Cell Fate; B. Deregulation of Myc in Tumor Development
- C. Myc as a Therapeutic Target for Human CancerII. Mnt: The Key Transcriptional Regulator of the Myc/Max/Mxd Network; A. Discovery and Characterization of Mnt; B. Mnt, the Major Myc Antagonist; C. Effects of Mnt Deficiency; D. Relief of Mnt-Mediated Repression: The Critical Event for Myc Target Gene Activation; E. Mnt to Be or Not to Be a Tumor Suppressor; III. Concluding Remarks; Acknowledgments; References; Chapter 4: Lytic Cycle Switches of Oncogenic Human Gammaherpesviruses; I. Two Life Cycles of EBV and KSHV: Latency and Lytic Replication; II. Virally Encoded Lytic Cycle Activator Genes